Table 3.
Multivariate analysis of survival time.
| Prognostic factors | Univariate analysis | ||
|---|---|---|---|
| Median OS (day) | p value | HR (95% CI) | |
| Year | 0.7386 | 0.90 (0.49-1.67) | |
| 2010 - 2015 | 84 | ||
| 2015 - 2020 | 92 | ||
| Gender | 0.6423 | 1.16 (0.62-2.16) | |
| Female | 83.5 | ||
| Male | 110 | ||
| Age*a | 0.0176 | 0.49 (0.26-0.92) | |
| < 65 Y | 164.5 | ||
| ≥ 65 Y | 63 | ||
| Tumor size | 0.8099 | ||
| < 3cm | 83 | ||
| 3~5cm | 102.5 | ||
| 5~9cm | 88.5 | ||
| ≥ 9cm | 50.5 | ||
| Stage* (AJCC 2017) | 0.0191 | ||
| IV A | 633.5 | ||
| IV B | 92 | ||
| IV C | 73.5 | ||
| Treatment | |||
| Surgery | 88.5 | 0.4158 | 0.69 (0.23-2.03) |
| Non-surgery | 53 | ||
| Radical operation* | 472 | 0.0261 | 0.37 (0.18-0.76) |
| Palliative operation | 82 | ||
| Tracheotomy | 92 | 0.2059 | 1.67 (0.62-4.46) |
| Non-tracheotomy | 85 | ||
| Radiotherapy* | 220 | 0.0136 | 0.44 (0.24-0.82) |
| Non-Radiotherapy | 75.5 | ||
| Chemotherapy | 150 | 0.2709 | 0.70 (0.38-1.30) |
| Non-chemotherapy | 82 | ||
| Multidisciplinary synthetic therapyb | |||
| Surgery and Radiotherapy* | 220 | 0.0268 | 0.44 (0.21-0.90) |
| Surgery and Chemotherapy | 110 | 0.7019 | 0.83 (0.33-2.09) |
| Surgery, Radiotherapy and Chemotherapy* | 220 | 0.0334 | 0.46 (0.21-1.01) |
| Surgery only | 81 | ||
OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.
a
Asterisk mark means p< 0.05.
b
All patients who underwent multidisciplinary synthetic therapy were compared with patients who received surgery only.